Skip to content

Esperion Therapeutics ESPR Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin15%-2.7pp17.7%+151pp-133.7%+104pp-237.8%+51.2pp
EBITDA margin15%-2.7pp17.7%+151pp-133.6%+104pp-237.2%+51.1pp
Efficiency
Asset turnover-0.2×1.2×+0.7×0.5×+0.3×0.2×0.0×
Liquidity
Current ratio1.5×+0.2×1.4×+0.1×1.3×-1.4×2.7×-1.8×
Quick ratio1.2×+0.2×+0.1×0.9×-1.4×2.3×-1.7×
Cash ratio0.6×0.0×0.6×+0.1×0.5×-0.8×1.4×-2.2×
Leverage
Debt-to-assets0.3×-0.1×0.4×+0.4×0.0×0.0×
Net debt / EBITDA-0.2×-0.2×
Interest coverage0.7×-0.3×+3.6×-2.6×+0.5×-3.2×+1.7×
Per Share
Book value per share-$1.45+30.0%-$2.08+52.9%-$4.41+9.5%-$4.88+28.4%
Valuation
Market capitalization$811.73M+283%$433.48M+27.5%$340.02M-25.9%$459.05M+47.3%
Enterprise value$810.81M+233%$435M+65.8%$262.34M-21.8%$335.32M+514%
Price / sales1.9×+1.1×1.3×-1.6×2.9×-3.2×6.1×+2.1×
EV / EBITDA10.7×7.4×
EV / sales1.9×+1.0×1.3×-0.9×2.3×-2.2×4.4×+3.7×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Esperion Therapeutics's ratios come from?
Every ratio is computed from Esperion Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.